New research by the Human Brain Project has found that in the brains of patients with epilepsy, changes in large scale neuronal activations can be detected in the brain’s resting state activity, even when no seizure is ongoing. The non-invasive approach could lead to a new method to aid epilepsy diagnostics.
Caregivers of adults with epilepsy were recruited to participate in an online survey examining health, well-being, COVID-19 experiences, and caregiver burden from October-December, 2020.
Perampanel was shown to be well tolerated and effective in the treatment of children and adolescents with epilepsy, according to study findings published in Brain and Development.
CBD
Purple Day®, webinars, our upcoming 25th Anniversary Gala, and more in this update!
SUDEP
Sudden Unexpected Death in Epilepsy (SUDEP) affected several aspects of the day-to-day lives of bereaved relatives. Though methods of coping were similar to the usual strategies adopted by all bereaved relatives, advocacy work related to raising awareness about epilepsy and SUDEP was unique to this group.
Genetics, Pediatric Epilepsy
The latest research on cannabidiol and seizures, the possible cause of infantile and epileptic spasms syndrome, the brain's immune system, and more in this issue of Epilepsy Research News.
Pediatric Epilepsy
Certain structures within the brains of children with Angelman syndrome were altered compared with unaffected children of the same age, an MRI study concluded.
A decision tool using a small number of historical clinical features accurately predicts the probability of epilepsy. In indeterminate cases, AI-assisted EEG helps resolve uncertainty. This tool holds promise for use by healthcare workers without specialty epilepsy training if validated in an independent cohort.
Pediatric Epilepsy
Differences in sense of control, cognitive inhibition, and selective attention in pediatric functional seizures (FS) versus matched controls implicate these as potential novel treatment targets. Retraining and Control Therapy (ReACT), which targets these factors, has been shown in a randomized controlled trial to be effective in improving pediatric FS with 82% of patients having complete symptom remission at 60 days following treatment.
